Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valter Torri

Showing results (201-210 of 228) with videos related to

Pageof 23
Sort By:
Lung Cancer (Amsterdam, Netherlands)|November 2, 2023
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitorsSara Manglaviti, Marta Bini, Giulia Apollonio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2017
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab MonotherapyEmanuele Zucca, Annarita Conconi, Giovanni Martinelli, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2022
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysisGiuseppe Viscardi, Antonino C Tralongo, Francesco Massari, et al.
Trials|July 27, 2020
Expression levels of circulating miRNAs as biomarkers during multimodal treatment of rectal cancer - TiMiSNAR-mirna: a substudy of the TiMiSNAR Trial (NCT03962088)Igor Monsellato, Elisabetta Garibaldi, Elisa Cassinotti, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trialMarco Platania, Felice Pasini, Luca Porcu, et al.
Journal of the National Cancer Institute|April 19, 2007
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trialStefano Cascinu, Roberto Labianca, Carlo Barone, et al.
Cancer Treatment Reviews|October 27, 2018
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)Martina Imbimbo, Margaret Ottaviano, Milena Vitali, et al.
BMC Cancer|February 19, 2020
Correction to: Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)Igor Monsellato, Filippo Alongi, Elisa Bertocchi, et al.
BMC Cancer|December 18, 2019
Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)Igor Monsellato, Filippo Alongi, Elisa Bertocchi, et al.
Oncotarget|January 8, 2019
Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Pageof 23

Showing results (201-210 of 228) with videos related to

Sort By:
Pageof 23
Lung Cancer (Amsterdam, Netherlands)|November 2, 2023
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitorsSara Manglaviti, Marta Bini, Giulia Apollonio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2017
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab MonotherapyEmanuele Zucca, Annarita Conconi, Giovanni Martinelli, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2022
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysisGiuseppe Viscardi, Antonino C Tralongo, Francesco Massari, et al.
Trials|July 27, 2020
Expression levels of circulating miRNAs as biomarkers during multimodal treatment of rectal cancer - TiMiSNAR-mirna: a substudy of the TiMiSNAR Trial (NCT03962088)Igor Monsellato, Elisabetta Garibaldi, Elisa Cassinotti, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trialMarco Platania, Felice Pasini, Luca Porcu, et al.
Journal of the National Cancer Institute|April 19, 2007
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trialStefano Cascinu, Roberto Labianca, Carlo Barone, et al.
Cancer Treatment Reviews|October 27, 2018
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)Martina Imbimbo, Margaret Ottaviano, Milena Vitali, et al.
BMC Cancer|February 19, 2020
Correction to: Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)Igor Monsellato, Filippo Alongi, Elisa Bertocchi, et al.
BMC Cancer|December 18, 2019
Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)Igor Monsellato, Filippo Alongi, Elisa Bertocchi, et al.
Oncotarget|January 8, 2019
Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Pageof 23